|
1
|
Strowd RE III, Holdhoff M and Grossman SA:
Chemotherapy for treatment of grade II gliomas. Oncology (Williston
Park). 28:1036–1043. 2014.PubMed/NCBI
|
|
2
|
Pedeutour-Braccini Z, Burel-Vandenbos F,
Gozé C, Roger C, Bazin A, Costes-Martineau V, Duffau H and Rigau V:
Microfoci of malignant progression in diffuse low-grade gliomas:
Towards the creation of an intermediate grade in glioma
classification? Virchows Arch. 466:433–444. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chamberlain MC: Glioblastoma in the
Elderly. Current Understanding and Treatment of Gliomas. 1–170.
2015.
|
|
4
|
Friedmann-Morvinski D: Glioblastoma
heterogeneity and cancer cell plasticity. Crit Rev Oncog.
19:327–336. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang X, Zhao HY, Zhang FC, Sun Y, Xiong ZY
and Jiang XB: Dendritic cell-based vaccine for the treatment of
malignant glioma: A systematic review. Cancer Invest. 32:451–457.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Altieri R, Agnoletti A, Quattrucci F,
Garbossa D, Specchia FM Calamo, Bozzaro M, Fornaro R, Mencarani C,
Lanotte M, Spaziante R and Ducati A: Molecular biology of gliomas:
Present and future challenges. Transl Med UniSa. 10:29–37.
2014.PubMed/NCBI
|
|
7
|
Simonetti G, Gaviani P, Innocenti A,
Botturi A, Lamperti E and Silvani A: Update on treatment strategies
for anaplastic glioma: A review of literature. Neurol Sci.
35:977–981. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Okita Y, Nonaka M, Umehara T, Kanemura Y,
Kodama Y, Mano M and Nakajima S: Efficacy of temozolomide and
bevacizumab for the treatment of leptomeningeal dissemination of
recurrent glioblastoma: A case report. Oncol Lett. 9:1885–1888.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kalkan R, Atli Eİ, Özdemir M, Çiftçi E,
Aydin HE, Artan S and Arslantaş A: IDH1 mutations is prognostic
marker for primary glioblastoma multiforme but MGMT
hypermethylation is not prognostic for primary glioblastoma
multiforme. Gene. 554:81–86. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang Y, Wang SX, Ma JW, Li HY, Ye JC, Xie
SM, Du B and Zhong XY: EGCG inhibits properties of glioma stem-like
cells and synergizes with temozolomide through downregulation of
P-glycoprotein inhibition. J Neurooncol. 121:41–52. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Turner KM, Sun Y, Ji P, Granberg KJ,
Bernard B, Hu L, Cogdell DE, Zhou X, Yli-Harja O and Nykter M:
Genomically amplified Akt3 activates DNA repair pathway and
promotes glioma progression. Proc Natl Acad Sci USA. 112:pp.
3421–3426. 2015; View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Barber NA and Ganti AK: Pulmonary
toxicities from targeted therapies: A review. Target Oncol.
6:235–43. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kuo PL, Hsu YL and Cho CY: Plumbagin
induces G2-M arrest and autophagy by inhibiting the AKT/mammalian
target of rapamycin pathway in breast cancer cells. Mol Cancer
Ther. 5:3209–3221. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zangari M, Cavallo F and Tricot G:
Farnesyltransferase inhibitors and rapamycin in the treatment of
multiple myeloma. Curr Pharm Biotechnol. 7:449–453. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tang JH, Ma ZX, Huang GH, Xu QF, Xiang Y,
Li N, Sidlauskas K, Zhang EE and Lv SQ: Downregulation of HIF-1a
sensitizes U251 glioma cells to the temozolomide (TMZ) treatment.
Exp Cell Res. 343:148–158. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kouroussis C, Vamvakas L, Vardakis N,
Kotsakis A, Kalykaki A, Kalbakis K, Saridaki Z, Kentepozidis N,
Giassas S and Georgoulias V: Continuous administration of daily
low-dose temozolomide in pretreated patients with advanced
non-small cell lung cancer: A phase II study. Oncology. 76:112–117.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu H, Cao Y, Tong T, Shi J, Zhang Y, Yang
Y and Liu C: Autophagy in atherosclerosis: A phenomenon found in
human carotid atherosclerotic plaques. Chin Med J (Engl).
128:69–74. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sheng R and Qin ZH: The divergent roles of
autophagy in ischemia and preconditioning. Acta Pharmacol Sin.
36:411–420. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gewirtz DA: Autophagy and senescence in
cancer therapy. J Cell Physiol. 229:6–9. 2014.PubMed/NCBI
|
|
20
|
Morselli E, Galluzzi L, Kepp O, Vicencio
JM, Criollo A, Maiuri MC and Kroemer G: Anti- and pro-tumor
functions of autophagy. Biochim Biophys Acta. 1793:1524–1532. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kondo Y and Kondo S: Autophagy and cancer
therapy. Autophagy. 2:85–90. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mareninova O, Jail W, Elperin J, Lotshaw
E, Pimiental M, Reicher B, Gukovsky I and Gukovskaya A: LC3
overexpression perturbs pancreatic acinar cell homeostasis and
alters pancreatitis responses. FASEB J. 30 1 Suppl 920:S122016.
|
|
23
|
Xiong Y, Yepuri G, Forbiteh M, Yu Y,
Montani JP, Yang Z and Ming XF: ARG2 impairs endothelial autophagy
through regulation of mTOR and PRKAA/AMPK signaling in advanced
atherosclerosis. Autophagy. 10:2223–2238. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Luo L, Lu AM, Wang Y, Hong A, Chen Y, Hu
J, Li X and Qin ZH: Chronic resistance training activates autophagy
and reduces apoptosis of muscle cells by modulating IGF-1 and its
receptors, Akt/mTOR and Akt/FOXO3a signaling in aged rats. Exp
Gerontol. 48:427–436. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang MC, Loh JK, Li YY, Huang WS, Chou CH,
Cheng JT, Wang YT, Lieu AS, Howng SL, Hong YR and Chou AK: Bcl2L12
with a BH3-like domain in regulating apoptosis and TMZ-induced
autophagy: A prospective combination of ABT-737 and TMZ for
treating glioma. Int J Oncol. 46:1304–1316. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zou Y, Wang Q, Li B, Xie B and Wang W:
Temozolomide induces autophagy via ATM-AMPK-ULK1 pathways in
glioma. Mol Med Rep. 10:411–486. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zheng DM, Bian Z, Furuya N, Trejo JA
Oliva, Takeda-Ezaki M, Takahashi K, Hiraoka Y, Mineki R, Taka H and
Ikeda S: A treadmill exercise reactivates the signaling of the
mammalian target of rapamycin (mTOR) in the skeletal muscles of
starved mice. Biochem Biophys Res Commun. 456:519–526. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sarkar S: Regulation of autophagy by
mTOR-dependent and mTOR-independent pathways: Autophagy dysfunction
in neurodegenerative diseases and therapeutic application of
autophagy enhancers. Biochem Soc Trans. 41:1103–1130. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kubrusly MS, Corrêa-Giannella ML,
Bellodi-Privato M, de Sá SV, de Oliveira CP, Soares IC, Wakamatsu
A, Alves VA, Giannella-Neto D, Bacchella T, et al: A role for
mammalian target of rapamycin (mTOR) pathway in non-alcoholic
steatohepatitis related-cirrhosis. Histol Histopathol.
25:1123–1131. 2010.PubMed/NCBI
|
|
30
|
Zhang J, Cao J, Weng Q, Wu R, Yan Y, Jing
H, Zhu H, He Q and Yang B: Suppression of hypoxia-inducible factor
1α (HIF-1α) by tirapazamine is dependent on eIF2α phosphorylation
rather than the mTORC1/4E-BP1 pathway. PLoS One. 5:e139102010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Guan L, Song K, Pysz MA, Curry KJ, Hizli
AA, Danielpour D, Black AR and Black JD: Protein kinase C-mediated
downregulation of cyclin D1 involves activation of the
translational repressor 4E-BP1 via a phosphoinositide
3-kinase/Akt-independent, protein phosphatase 2A-dependent
mechanism in intestinal epithelial cells. J Biol Chem.
282:14213–14225. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fan QW and Weiss WA: Targeting the
RTK-PI3K-mTOR axis in malignant glioma: Overcoming resistance. Curr
Top Microbiol Immunol. 347:279–96. 2010.PubMed/NCBI
|
|
33
|
Thoury A, Descatoire V, Kotelevets L,
Kannengiesser C, Bertrand G, Theou-Anton N, Frey C, Genestie C,
Raymond E, Chastre E, et al: Evidence for different expression
profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high
grade endometrial carcinomas in a cohort of consecutive women.
Occurrence of PIK3CA and K-Ras mutations and microsatellite
instability. Histol Histopathol. 29:1455–1466. 2014.PubMed/NCBI
|
|
34
|
Wang S, Wu M, Yao G, Zhang J and Zhou J:
The cytoplasmic tail of FPC antagonizes the full-length protein in
the regulation of mTOR pathway. PLoS One. 9:e956302014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ye LX, Yu J, Liang YX, Zeng JS, Huang RX
and Liao SJ: Beclin 1 knockdown retards re-endothelialization and
exacerbates neointimal formation via a crosstalk between autophagy
and apoptosis. Atherosclerosis. 237:146–154. 2014. View Article : Google Scholar : PubMed/NCBI
|
